Elusys Therapeutics is a NightHawk Biosciences company that leverages immune-stimulatory and immune-derived therapies to combat infectious disease. Our anthrax antitoxin obiltoxaximab, licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in the United Kingdom and the European Union, is a medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack. We are also developing proprietary platform technologies designed to target emerging biological threats with the mission to deploy biodefense solutions that enable fast, effective treatment and durable protection to defend tomorrow today.